Thousands of patients to benefit from new daily pill for serious heart condition following co‑ordinated MHRA and NICE decisions
MHRA authorised the once‑daily pill aficamten for adults with symptomatic obstructive hypertrophic cardiomyopathy and at the same time NICE published final…
Impact analysis · 55/100 · AI-assisted priority
This score prioritizes research; it does not predict an outcome. Method and limitations.
What happened
MHRA authorised the once‑daily pill aficamten for adults with symptomatic obstructive hypertrophic cardiomyopathy and at the same time NICE published final guidance recommending its use, enabling patients to access treatment more quickly.
Quantitative evidence
- Approximately 6,600 people in England eligible
- Aficamten authorised 29 July 2026
- NICE guidance published two weeks faster than standard
- Exact comparative efficacy versus mavacamten not quantified
- Cost or price data beyond confidential discount not disclosed
Affected entities
Analysis
The following contextual analysis is AI-assisted and separated from the reported primary-source record above.
Scientific context
Aficamten is a reversible cardiac myosin inhibitor that reduces hypertrophic obstruction and improves exercise capacity in obstructive HCM.
Market context
The coordination accelerates patient access and may streamline NHS delivery; Cytokinetics, Inc is the marketing authorisation holder.
Legal and regulatory context
MHRA authorised the drug and NICE issued final guidance concurrently, reflecting a streamlined regulatory‑health technology assessment approach.
Sources
For informational use only. Verify decisions against the linked regulator or primary source.
Evidence & limits
Source: Open the source record
- Record identifier
- 078b3fa805b98676bcbddd10053421f82faee103a7f63f5ea4b0d40a85ea99a6
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- 2026-07-30T130927Z
What it supports. The linked authority’s action, within the product, indication, jurisdiction, and procedural stage stated in that record.
Limits. A committee opinion, draft, or announcement does not by itself establish final authorization. The summary and contextual analysis are AI-assisted; a source link does not establish human review.
Connection basis. Related profiles are normalized name mentions in article text. A mention does not establish a legal relationship.